One place where we can learn more about psoriasis in people of color is in clinical trials. However, people with skin of color are drastically underrepresented in clinical trials for dermatology. The lack of diversity in clinical trials means that medications developed for conditions like psoriasis may not work as effectively for people with skin of color, and ultimately, the health equity gap continues to widen.

Clinical studies are an essential part of biopharmaceutical research on the journey to discover, develop and deliver new solutions to people living with severe diseases. This Clinical Trial Awareness week, UCB thanks all of the participants in UCB studies and the dedicated researchers doing this important work.

The journey of developing inclusive and innovative solutions to our clinical trials approach began several years ago at UCB, and we continue to progress towards this goal every day, laser-focused on improving representation in clinical studies. This Clinical Trials Day, we’re highlighting the work UCB employees are doing to address health inequities in clinical trials through digital business transformation, and approaches like decentralized clinical trials, leveraging real-world evidence, and personalized tools to enhance the patient experience.    

As part of our Digital Business Transformation, UCB teams participated in a hackathon to improve the quality and efficiency of clinical study design and data analysis, ultimately a win for the patients we serve. Winners to be announced soon.

Diversity and inclusion in clinical trials is critical, and UCB is working to find new ways to connect to unique patient populations through our technological and data driven approaches. Kim Doggett, Head of Site Engagement, and her team focus on how they can provide value to patients by finding new ways to build relationships with clinical investigative sites to ensure we are reaching the targeted patient populations where we hope to provide meaningful solutions. Read more from Kim as she shares UCB’s diversity and inclusion approach to clinical trials.